China Biologic Produ (CBPO) Stock Price, Quote, News and Overview
NASDAQ:CBPO - Nasdaq -
CBPO Quote, Performance and Key Statistics
119.99
+1.98 (+1.68%)
The current stock price of CBPO is 119.99 null. In the past month the price increased by 2.25%. In the past year, price increased by 12.37%.
About CBPO
Company Profile
China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company's principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.
Company Info
China Biologic Produ
18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT
BEIJING F4 100125
CEO: Joseph Chow
Phone: 86-10-6598-3111
China Biologic Produ / CBPO FAQ
What is the stock price of China Biologic Produ today?
The current stock price of CBPO is 119.99 null. The price increased by 1.68% in the last trading session.
What is the ticker symbol for China Biologic Produ stock?
The exchange symbol of China Biologic Produ is CBPO and it is listed on the Nasdaq exchange.
On which exchange is CBPO stock listed?
CBPO stock is listed on the Nasdaq exchange.
What is China Biologic Produ worth?
China Biologic Produ (CBPO) has a market capitalization of 4.72B null. This makes CBPO a Mid Cap stock.
What are the support and resistance levels for China Biologic Produ (CBPO) stock?
China Biologic Produ (CBPO) has a support level at 119.04 and a resistance level at 120. Check the full technical report for a detailed analysis of CBPO support and resistance levels.
Should I buy China Biologic Produ (CBPO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CBPO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CBPO, evaluating the profitability, health, valuation and growth aspects
- China Biologic Produ (CBPO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- China Biologic Produ (CBPO) Sales and EPS estimates to see what analysts future expectations are.
- China Biologic Produ (CBPO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- China Biologic Produ (CBPO) Insider and Institutional Ownership to learn about the owners and their transactions.
- China Biologic Produ (CBPO) Stock Chart to make your own analysis
- China Biologic Produ (CBPO) Latest news and press-releases to stay up to date.
Does China Biologic Produ (CBPO) stock pay dividends?
CBPO does not pay a dividend.
What is the Price/Earnings (PE) ratio of China Biologic Produ (CBPO)?
The PE ratio for China Biologic Produ (CBPO) is 30.07. This is based on the reported non-GAAP earnings per share of 3.99 and the current share price of 119.99 null. Check the full fundamental report for a full analysis of the valuation metrics for CBPO.
CBPO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CBPO. When comparing the yearly performance of all stocks, CBPO is a bad performer in the overall market: 77.21% of all stocks are doing better.
CBPO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CBPO. CBPO has an excellent financial health rating, but there are some minor concerns on its profitability.
CBPO Financial Highlights
Over the last trailing twelve months CBPO reported a non-GAAP Earnings per Share(EPS) of 3.99. The EPS decreased by -6.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.04% | ||
| ROA | 7.12% | ||
| ROE | 7.71% | ||
| Debt/Equity | 0 |